Compare Mesoblast Limited (MESO) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs NRG Energy Inc — how do they compare? Mesoblast Limited trades at $16.87 (market cap $2.21B), while NRG Energy Inc trades at $121.88 (market cap $24.83B). The key difference: NRG Energy Inc is far larger — about 11.2× Mesoblast Limited's market cap, and NRG Energy Inc pays a 1.61% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | NRG | |
|---|---|---|
Market Cap | $2.21B | $24.83B |
Sector | Technology | Utilities |
52-Week High | $20.96 | $184.03 |
52-Week Low | $12.88 | $117.04 |
Enterprise Value | $2.21B | $48.79B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
NRG Energy trades at $118.91, down 0.66% today, with a bearish technical signal. Recent Q2 2026 earnings missed estimates, but revenue grew 11% year-over-year. The company is expanding with a 1.2 GW Texas data-center power project, targeting long-term EBITDA growth. Valuation metrics show a P/E of 30.76 and P/S of 0.72, with strong ROE at 26.77% but modest net income margin of 2.56%. Cash flow trends are volatile, with 2025 net cash flow at $3.83B but a projected decline in 2026.
Outlook: Growth driven by data-center demand and strategic acquisitions offers upside, but high debt and earnings misses pose risks. Analyst consensus is bullish with a $207.83 price target, though technical weakness and rising interest costs require caution. Key opportunities include hyperscaler partnerships, while risks involve leverage and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
